Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now that completed early enrollment is not in play. Is anyone concerned about a delay in Sunrise?
Since Opdivo is now pounding the airwaves, is there any affect on US sites? If you look at it logically, and in a patients perspective, would you not be tempted to abandoned Sunrise for Opdivo? If you were a candidate of course..
All the best,
John
It's my opinion that the 175 mm is a golden parachute.
Shareholders have taken on the burden, in spite of mismanagement and delay from the beginning, IMO.
I've traveled this road before, I'm voting no, regardless if it matters or not. It's priciple for me.
All the best,
John
And Cancer to canabalize Cancer..
How about Crestor having the chemo effect on viruses to allow a more robust symmetrical PS target?
All the best, and you've made the most exceptional description tonight. "Manipulate the PS effect".. Love that!
John
This post has flaws..EOM
You're welcome..
Just wanted to say thank you..
All the best,
John
You're welcome..
I've about to run out of post.
Just wanted to thank you..
Cancer cells find a way to survive, just like life and death on earth, it's a balance and evolution, or divine structure. Either way, it's made to find an equilibrium and survive.
With that said, everything has a Genesis, and discovering such would help understand how survival happens.
Where does one begin the search for a Cancer Genesis? Sub-atomically? Atomically?
Does Cancer Genesis matter, or is it more valuable to understand the equilibrium?
To find equilibrium one would need to know what tilts the cancers pendulum, from survival to exposure.
To discover a pendulum one would need to find a common theme between survival and exposure.
What common theme is more valuable to survival? What common theme is more important to exposure?
Is Phosphatidylserine a common theme? A Cancer Pendulum Common Denominator?
All the best,
John
I'm thinking Bavi has NAb (neutralizing antibody) characteristics, and was looking for someone to bounce a few ideas around...
All the best,
John
Do you have a Phd in microbiology?
All the best,
John
Definitely better to have breakthrough designation. Although there is value in Fast Track as opposed to not.
This link shows approvals for FT and BTD..
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm2007016.htm
Thanks for bringing some clarity to the subject.
All the best,
John
It would be of value to do a comparable with such information, if not for Peregrine, then others.. Saying most or all companies receive FT is broad brushed and needs clarity. I do agree that BTD is more validating, but how many breakthrough designated drugs are in Phase III? I don't recall any?
Is there any value or reasoning to award BTD to a Phase III drug?
All the best,
John
Given that the price is $1.50 and P3 is more than halfway done, isn't it worth consideration for investment?
Are you certain that antiPS is worthless, or more blinded by disdain?
Bavituximab is not an icon, but yes some worship it as it it were. However, for me it's just science, and possibly a "cog in the wheel" to cancers immunostimulatory evasiveness.
"So you're telling me that there is a chance"
All the best,
John
In theory, in regards to cancer, the idea would be to find a Pathogenic Common Denominator, a common theme to cancer metastasis. A Cancer Genesis Common Denominator, so to speak..
We know that PD1 and Ctla4 are both to far up stream to be considered Genesis.. CD47 is a possibility..
Apoptotic transdifferentiation? Maybe..
How about Phosphatidylserine in a pathogenic necrotic environment? Maybe not Genesis, but how about the Pathogenic Common Denominator?
All the best,
John
Avid expansion is a definite positive, and if you're Into puzzle pieces, (no offense biopharm) then so be it. However, if you're looking for difinitives, then one needs to question the lack of partnerships. After all why would a BP be threatened by a combination adjuvant?
As for dilution, yes it is problematic for shareholders, but not any different from many other small biotechs.. The only thing that's going to keep our head above water until delineating data becomes available, is someone in the know, or a collaborating commitment, IMO.
all the best,
John
True valuation is created by validated clinical data. For example see PCYC.. Not passing out pump articles at an Amway convention, IMO.
Until this has passed we're not going anywhere, IMO.
All the best,
John
Lemmings,